| abstract |
The invention relates to the field of immunology, immunoallergy and, in particular, the use of adjuvants or carriers in order to modulate the immunological response to allergens. The technical objective of the invention is: to produce a therapeutic or prophylactic pharmaceutical preparation using bacterial proteoliposomes, which, when applied to allergic individuals, transforms the Th2- and IgE-dependent allergic response into a protective Th1 response; and to prevent the appearance and development of allergies in not-yet allergic individuals. The vaccine composition consists of proteoliposomes of gram-negative bacteria coupled with allergens and, optionally, other antigens or adjuvants. The invention also relates to the method of producing the inventive vaccine composition and to the two-dose schedule for immunisation with said vaccine composition. |